ValiRx Unit Receives Intention to Grant European Patent for Anti-Cancer Peptide

05:10 AM EDT, 08/10/2026 (MT Newswires) -- ValiRx's (VAL.L) said Monday its majority-owned subsidiary Cytolytix received a formal notification from the European Patent Office of its intention to grant a European patent covering anti-cancer polyleucine-based peptides. Once granted, the patent will be the second European patent received by the life science company following the European grant of the original peptide formulation patent in May.